macular edema caused by fingolimod in multiple sclerosis: a case report

نویسندگان

همایون نیک خواه

h nikkhah ophthalmic research center, shahid beheshti university of medical sciences, tehran, iranدانشگاه علوم پزشکی شهید بهشتی- تهران- ایران حمید احمدیه

h ahmadieh ophthalmic research center, shahid beheshti university of medical sciences, tehran, iranدانشگاه علوم پزشکی شهید بهشتی- تهران- ایران جوار رضایی

j rezaei ophthalmic research center, shahid beheshti university of medical sciences, tehran, iranدانشگاه علوم پزشکی شهید بهشتی- تهران- ایران ندا عین اللهی

n einollahi ophthalmic research center, shahid beheshti university of medical sciences, tehran, iranدانشگاه علوم پزشکی شهید بهشتی- تهران- ایران محمدعلی صحرائیان

چکیده

purpose: to report a case of severe macular edema following the taking of fingolimod in multiple sclerosis. case report: a 34-year-old woman with a long history of relapsing-remitting multiple sclerosis presented complaining of blurred vision in the left eye that started 1 week before the presentation. she had been taking fingolimod for 4 months. she was not diabetic and had no history of uveitis but reported an episode of retrobulbar optic neuritis in both eyes. the initial ophthalmic examination, which was performed 2 weeks before initiating fingolimod, revealed a best corrected visual acuity (bcva) of 20/25 ou and no ocular abnormalities. upon the recent presentation, bcva was 20/25 od and 20/70 os and there was no afferent papillary defect. the examination of anterior segment and anterior vitreous was unremarkable. retinal examination of the left eye revealed cystoid macular edema with no other inflammatory signs or vascular changes. the findings of spectral domain optical coherence tomography (sd-oct) were compatible with macular edema and indicated that the central macular thickness (cmt) was 605 microns. fingolimod was discontinued and sinarolac was started three times daily. after 6 weeks, bcva was 20/25 od and 20/30 os. macular edema was resolved clinically and sd-oct exhibited a significant reduction in macular edema with a cmt of 277 microns. conclusion: fingolimod-associated macular edema is a benign complication of the drug used for multiple sclerosis and. this complication responds well to the drug discontinuation and topical non-steroidal anti-inflammatory administration.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod

Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...

متن کامل

Cystoid macular edema associated with fingolimod use for multiple sclerosis.

Fingolimod is the first oral drug approved by the US Food and Drug Administration for multiple sclerosis (MS). It is a sphingosine-1phosphate–receptor modulator that prevents lymphocyte egress from lymph nodes and enhances astrocyte function. In this retrospective case series, 4 eyes from 3 patients developed cystoid macular edema (CME) after initiating fingolimod therapy. The study was approve...

متن کامل

Continuing fingolimod after development of macular edema: A case report

Fingolimod is the first effective oral agent in widespread use for relapsing-remitting multiple sclerosis (MS), but it can cause macular edema (ME) as an uncommon complication.MEmay be mild and asymptomatic, but it can also produce visual impairment. The mechanism of fingolimod-associated ME (FAME) is thought to be through sphingosine-1-phosphate receptor antagonism, affecting endothelial integ...

متن کامل

Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis

INTRODUCTION Generally, fingolimod administration is simply discontinued when fingolimod-associated macular edema (ME) appears, and the majority of cases are said to recover spontaneously. However, to the best of our knowledge, this is the 1st report regarding improvement of ME without discontinuation of fingolimod administration. CASE PRESENTATION The patient was a 66-year-old woman with rel...

متن کامل

[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].

CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and O...

متن کامل

Acute onset of fingolimod-associated macular edema

Purpose Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular edema usually resolves upon discontinuation of fingolimod; however, the time required for resolution ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
بینا

جلد ۲۱، شماره ۱، صفحات ۷۰-۷۴

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023